Effect of Candesartan on cause-specific Mortality in heart failure patients. The Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program

Patients with heart failure are at increased risk of sudden death and death attributed to progressive pump failure. We assessed the effect of candesartan on cause-specific mortality in patients enrolled in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) pr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation (New York, N.Y.) N.Y.), 2004-10, Vol.110 (15), p.2180-2183
Hauptverfasser:	SOLOMON, Scott D, DUOLAO WANG, POCOCK, Stuart, PFEFFER, Marc A, FINN, Peter, SKALI, Hicham, ZORNOFF, Leonardo, MCMURRAY, John J. V, SWEDBERG, Karl, YUSUF, Salim, GRANGER, Christopher B, MICHELSON, Eric L
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Angiotensin II Type 1 Receptor Blockers - therapeutic use Benzimidazoles - therapeutic use Biological and medical sciences Blood and lymphatic vessels Canada - epidemiology Cardiac and Cardiovascular Systems Cardiac/epidemiology/prevention & control Cardiology. Vascular system Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control Cardiovascular Diseases/mortality/prevention & control Cardiovascular system Cause of Death Congestive/drug therapy/mortality Death Death, Sudden, Cardiac - epidemiology Death, Sudden, Cardiac - prevention & control Disease Progression Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Emergency and intensive care: renal failure. Dialysis management Female Great Britain/epidemiology Heart Failure Heart Failure - drug therapy Heart Failure - mortality Humans Intensive care medicine Kardiologi Left/mortality/prevention & control Male Medical sciences Middle Aged Pharmacology. Drug treatments Proportional Hazards Models Single-Blind Method Sudden Sweden - epidemiology Tetrazoles - therapeutic use United Kingdom - epidemiology United States - epidemiology Vasodilator agents. Cerebral vasodilators Ventricular Dysfunction Ventricular Dysfunction, Left - mortality Ventricular Dysfunction, Left - prevention & control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Patients with heart failure are at increased risk of sudden death and death attributed to progressive pump failure. We assessed the effect of candesartan on cause-specific mortality in patients enrolled in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. The CHARM program consisted of 3 component trials that enrolled patients with symptomatic heart failure: CHARM-Alternative (n=2028; LVEF
ISSN:	0009-7322 1524-4539 1524-4539
DOI:	10.1161/01.CIR.0000144474.65922.AA